More stories
Bridging Worlds: Psychedelics, Community, and the Work of Our Time
In 2025, the psychedelic landscape is rich with possibility, and yet often fragmented. Psychedelic gatherings can feel like isolated islands, each with its own...
Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine...
MDMA drug developer Lykos Therapeutics has changed its name to Resilient Pharmaceuticals, Inc., Psychedelic Alpha understands. The move comes after British investor and philanthropist...
Matt Xavier -The Psychedelic DJ
From the Rave Scene to Psychedelic Therapy In this episode, Kyle Buller speaks with Matt Xavier, DJ, therapist, and author. The conversation took place...
AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B
AbbVie has today announced that it is set to acquire Gilgamesh Pharmaceuticals’ lead candidate, GM-2505 (aka bretisilocin, a serotonergic psychedelic), which is under development...
Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression
This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine for treatment-resistant depression. Last month, we...
July 2025 Psychedelic Patent Update
The Psychedelic Patent Update provides headline figures and data regarding published psychedelic patent applications and grants. We added 6 PCTs and 25 U.S. patent...
Dr Case Newsom – Creating Safe Spaces: The Zendo Project’s Approach to Psychedelic Support
PODCAST INSERT In this episode, Joe Moore sits down with Dr. Case Newsom, an emergency room physician in Denver and Medical Director for both...
The Psychedelics & Pain Symposium 2025
The Psychedelics & Pain Symposium 2025 is the only conference highlighting past, current, and ongoing investigations into how psychedelics can treat chronic pain and...
Growing Attention To Psychedelics For Pain, Physical & Neurological Conditions
By Kevin Lenaburg and Court Wing Psychedelics can be powerful treatments for chronic pain and other physical or neurological conditions. There is increasing awareness...
Kat Murti – Students for Sensible Drug Policy, Meta Censorship, and the Fight for...
PODCAST INSERT In this episode, Joe Moore is joined by Kat Murti, Executive Director of Students for Sensible Drug Policy (SSDP), the largest youth-led...
Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression
This morning, Reunion Neuroscience shared positive topline data from its Phase 2 trial of RE104 in postpartum depression (PPD), a study that saw 84...
Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection
The Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius) produces 5-MeO-DMT in its skin. Demand for that molecule now pressures a fragile animal. Retreats...
